MentionFox
Home › Executive changes › Werewolf Therapeutics, Inc.
Leadership changes · HOWL · SEC Form 8-K, Item 5.02

Leadership changes at Werewolf Therapeutics, Inc. (2026)

Before you join, sell to or invest in Werewolf Therapeutics, Inc.

MentionFox check on Werewolf Therapeutics, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/werewolf-therapeutics

  • Note: Layoff plan disclosed Feb 2026 (filing)

Check Werewolf Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Werewolf Therapeutics, Inc.?

Who joined and who left Werewolf Therapeutics, Inc. (HOWL)? 1 appointment reported on 2026-02-13, each cited to the company's own filing.

Michael Urban was named Vice President of Werewolf Therapeutics, Inc., effective February 13, 2026. As of November 14, 2026, Werewolf Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 13, 2026, naming 1 appointment (Form 8-K, February 13, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

MPM BioVentures 2014, L.P. also filed stake reports on 1 other company ↓

Sell to companies like Werewolf Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-02-13

Werewolf Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Werewolf Therapeutics, Inc. files it.

Layoffs on record: 1 filing or notice, latest 2026-02-13 (layoff filings and notices).

Also on the record for Werewolf Therapeutics, Inc.

DateRecordFigureOur pageSource
September 21, 2026Stake report, Schedule 13G, by MOLL PETER5.2% of the class5%+ stakesSource
July 2, 2026Stake report, Schedule 13D/A, by RA Capital Management, L.P.4.1% of the class5%+ stakesSource
June 26, 2026Stake report, Schedule 13D/A, by RA Capital Management, L.P.6% of the class5%+ stakesSource
June 22, 2026Stake report, Schedule 13D/A, by RA Capital Management, L.P.7.5% of the class5%+ stakesSource
June 15, 2026Stake report, Schedule 13D/A, by RA Capital Management, L.P.10.6% of the class5%+ stakesSource
May 14, 2026Stake report, Schedule 13D/A, by RA Capital Management, L.P.12.6% of the class5%+ stakesSource
May 12, 2026Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P.3.8% of the class5%+ stakesSource
May 5, 2026Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P.5.4% of the class5%+ stakesSource
February 11, 2026Stake report, Schedule 13G/A, by Longwood Fund III GP, LLC3.5% of the class5%+ stakesSource
January 16, 2026Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P.6.9% of the class5%+ stakesSource
December 29, 2025Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P.8.2% of the class5%+ stakesSource
December 3, 2025Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P.10% of the class5%+ stakesSource

Selling to them or working with them? See who runs Werewolf Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Werewolf Therapeutics, Inc. and the records around it.

Werewolf Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Werewolf Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Werewolf Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Werewolf Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 16 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-13InVice President2026-02-138-K, 2026-02-13

Who leads Werewolf Therapeutics, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Werewolf Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Werewolf Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Werewolf Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Vice President at Werewolf Therapeutics, Inc., with the record behind each one.

Find candidates like Vice President at Werewolf Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-02-13 · 8-K

Appointed: Michael Urban, Vice President, effective 2026-02-13

On February 12, 2026, the Company appointed Michael Urban, Vice President of Finance and Corporate Controller, as the Company's principal financial officer and principal accounting officer, effective February 13, 2026.

Also stated in this filing

  • Departure of Certain Officers As part of the Reduction, on February 9, 2026, the Company and each of Timothy W. Trost, Chief Financial Officer of the Company, and Dr. Randi Isaacs, M.D., Chief Medical Officer of the Company, agreed that Mr. Trost and Dr. Isaacs would resign as Chief Financial Officer and Chief Medical Officer, as applicable, effective February 13, 2026.
  • Both Mr. Trost and Dr. Isaacs are entitled to severance benefits in accordance with their employment agreements upon execution of a separation agreement and general release of claims comprising (i) an amount equal to nine months base salary, and (ii) company contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act for a period of nine months.
  • In addition, the separation agreements provide that the exercise period for stock options that are outstanding and vested as of the separation date will be extended from three months until the final exercise date, as such term is defined in the applicable option agreement.

Tools for this story

Each opens in a new tab, filled in for Werewolf Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/werewolf-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Werewolf Therapeutics, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/werewolf-therapeutics